B. Mau

What Type of Pivotal Study Design is Appropriate for an Investigational New Drug to Manage Chronic Angle Closure Glaucoma: Active Control or Placebo?

H. Chern, Yeong-Liang Lin, B. Mau, 2002 .

Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity.

G. Powis, B. Mau, Garth Powis, 1992, Biochemical pharmacology.

Compliance of Clinical Trial Consent Forms with International Guidelines: Analysis of Deficiencies

Yeong-Liang Lin, B. Mau, Chia-Hsin Huang, 2002 .

PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

C. Tzen, W. Cheng, B. Mau, 2008, Annals of Surgical Oncology.

Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones.

G. Powis, B. Mau, 1990, Free radical research communications.

Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds.

G. Powis, B. Mau, 1992, Biochemical pharmacology.

ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis?

C. Tzen, B. Mau, Tsu‐Yen Wu, 2007, Mitochondrion.

Analysis of disease-associated ND4 mutations: how do we know which mutation is pathogenic?

C. Tzen, B. Mau, Hsiu-Jun Hsu, 2007, Mitochondrion.

Identification of Human‐Specific Adaptation Sites of ATP6

C. Tzen, Horng-mo Lee, B. Mau, 2005, Annals of the New York Academy of Sciences.

Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.

C. Tzen, B. Mau, M. Wang, 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Analysis of CD117-negative gastrointestinal stromal tumors.

C. Tzen, B. Mau, 2005, World journal of gastroenterology.